Results Candesartan, the active metabolite of candesartan cilexetil, declined from Conclusions A longer persistence of the antagonistic effect at the receptor site than expected by the presence in plasma indicates a slow off-rate of candesartan cilexetil from in vivo receptors. This provides an additional rationale for the observed 24 h therapeutic activity of candesartan cilexeti1.
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alcohol from 12 h before until the end of each study day.
Tolerability was tested repeatedly by clinical examinations,
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Diastolic blood pressure data standard laboratory and ECG.
collected during the angiotensin II infusion at 3 min after increase of each dose step were used to fit individual dose-.. effect curves (i.e. the curves representing the relation
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The in vivo antagonistic effect, measured from the shift of course. As the receptor binding is saturable in contrast to the angiotensin II dose-effect curves as DR -1, was h. p.1.e. and DR -1, concentration equivalents (n x K;) have correlated to the plasma pharmacokinetics, measured from been used to eliminate this source of error.
h.p.l.e. (if. Figure 7) and from radioreceptor assay (if. ::x::- hypertension, where therapeutic doses between 4 and 16 mg once daily candesartan cilexetil had been established [27J.
We conclude that candesartan cilexetil is a highly potent, orally active angiotensin II antagonist in humans with a long duration of action providing a 24 h antagonistic activity after a single daily dose.
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